Comparison of Treatment Strategies for Patients With Clinical Stage T1-3/N2 Lung Cancer

doi:10.6004/jnccn.2019.7353

中山醫學大學機構典藏 CSMUIR > 中山醫學大學研究成果 > 期刊論文 > Item 310902500/24688

Please use this identifier to cite or link to this item: https://ir.csmu.edu.tw:8080/ir/handle/310902500/24688

Title:	Comparison of Treatment Strategies for Patients With Clinical Stage T1-3/N2 Lung Cancer
Authors:	Cheng, YF;Hung, WH;Chen, HC;Cheng, CY;Lin, CH;Lin, SH;Wang, BY
Date:	2020
Issue Date:	2022-08-09T08:06:24Z (UTC)
Publisher:	HARBORSIDE PRESS
ISSN:	1540-1405
Abstract:	Background: The therapeutic strategies for clinical stage T1-3N2 (cT1-3N2) lung cancer are controversial. For operable tumors, treatment can vary by center, region, and continent. This study aimed to identify the optimal therapeutic method and type of surgical strategy for cT1-3N2 lung cancer. Methods: This retrospective evaluation analyzed the records of 17,954 patients with cT1-3N2 lung cancer treated in 2010 through 2015 from the SEER database. The effects of different therapeutic methods and types of surgical strategies on overall survival (OS) were assessed. Univariate and multivariate analyses were performed using a Cox proportional hazards model. Results: The 5-year OS rates were 27.7% for patients with T1N2 disease, 21.8% for those with T2N2 disease, and 19.9% for T3N2 disease. Neoadjuvant therapy plus operation (OP) plus adjuvant therapy, and OP plus adjuvant therapy, provided better 5-year OS rates than OP alone or concurrent chemoradiotherapy (34.1%, 37.7%, 29.3%, and 16.1%, respectively). In the T1N2, T2N2, and T3N2 groups, lobectomy provided better 5-year OS than pneumonectomy, sublobectomy, and no surgery. Both univariate and multivariate analyses showed that young age, female sex, well-differentiated histologic grade, adenocarcinoma cell type, neoadjuvant and adjuvant therapy, lobectomy, and T1 stage were statistically associated with better 5-year OS rates. Conclusions: In cT1-3N2 lung cancer, multimodal treatments tended to provide better 5-year OS than OP alone or concurrent chemoradiotherapy. In addition, lobectomy was associated with better survival than other operative methods.
URI:	http://dx.doi.org/10.6004/jnccn.2019.7353 https://www.webofscience.com/wos/woscc/full-record/WOS:000512898500005 https://ir.csmu.edu.tw:8080/handle/310902500/24688
Relation:	JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK ,2020 ,v18 ,issue 2 ,p143-150
Appears in Collections:	[中山醫學大學研究成果] 期刊論文

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	202	View/Open

Loading...